Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 6/20 | 0.34 |
| ▸ | JAK3 | P52333 | 5/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | STAT5B | P51692 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182702 | 0.88 | KIT (0.40) | ITKJAK2JAK3PIK3C3SYK | |
| SCHEMBL4170524 | 0.86 | MEN1 (0.38) | ITKJAK2JAK3NTRK1PIK3C3 | |
| SCHEMBL4166686 | 0.82 | DHODH (0.40) | DHODHITKJAK2JAK3NTRK1 | |
| SCHEMBL13663535 | 0.78 | DHODH (0.48) | DHODHJAK2JAK3NTRK1PIK3C3 | |
| SCHEMBL4300039 | 0.77 | RET (0.46) | ITKRETAURKB | |
| SCHEMBL4162005 | 0.77 | JAK2 (0.39) | ITKJAK2JAK3NTRK1RET | |
| SCHEMBL4169624 | 0.77 | ITK (0.43) | DHODHITKJAK2JAK3NTRK1 | |
| SCHEMBL4303875 | 0.77 | JAK2 (0.49) | ITKJAK2JAK3NTRK1RET | |
| SCHEMBL4298197 | 0.76 | DHFR (0.46) | ITKJAK2JAK3SYKRET | |
| SCHEMBL4179956 | 0.76 | JAK2 (0.43) | DHODHITKJAK2JAK3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | claimed |
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | MAP3K1, MAP3K15, MAP3K5 | DHODH 3096/4885ITK 951/4885JAK2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.